About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Food and Crohn's Exacerbation Study (FACES) | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNANCT01926730

Food and Crohn's Exacerbation Study (FACES)

The proposed study is a randomized controlled trial of a limited restriction diet compared to a regular diet among patients with Crohn's disease (CD) in remission. At baseline, patients will complete ...

Lead sponsor: University of Pennsylvania•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Pennsylvania

Collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Crohn's and Colitis Foundation

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Patients must have an established diagnosis of CD.
•2. All patients must be in clinical remission at the time of entry into the study. Remission is defined as an aCDAI of less than 150.

Exclusion Criteria

•Inflammatory bowel disease (IBD) unspecified / Indeterminate colitis
•Total or sub-total colectomy, ileostomy, or colostomy
•Unable to read and speak English
•No internet access
•Steroids other than budesonide ≤6mg/day with the prior two weeks
•Perianal fistula or abscess with more than scant drainage
•Age less than 18 years
•Pregnant or breastfeeding women
•Unwilling to follow the study diet

Related studies

RECRUITINGPhase 3

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more

RECRUITINGPhase 4

Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

NCT06180382 · Crohn's Disease

RECRUITINGPhase 2

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883 · Inflammatory Bowel Diseases, Crohn's Disease

RECRUITINGPhase 3

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931 · Crohn's Disease

RECRUITINGPhase 2

DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease

NCT06918808 · Perianal Fistula Due to Crohn's Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 14, 2017Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment216

Start dateNov 2013

Last updatedFeb 14, 2017

Condition

Crohn's Disease

Locations shown

University of Pennsylvania

Philadelphia, Pennsylvania

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 14, 2017Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions